Biotechnology Industry Organization (BIO) CEO And Investor Conference To Highlight Topics That Will Fuel Continued Industry Growth And Investments In 2006
WASHINGTON, Jan. 12 /PRNewswire/ -- Over 2,000 companies, institutional investors, money managers and analysts will flock to the BIO CEO and Investor Conference on February 14-15 in New York City. The conference, now in its 8th year, is designed to educate new investors and media on the value, risks and rewards offered by the industry and to fuel continued industry growth and investments in 2006. Complimentary registration is open to qualified investors and members of the media at http://www.ceo.bio.org .
"Over the last five years biotechnology has matured into a more stable investment vehicle providing strong returns based on very predictable fundamentals," stated Stephen Sands Managing Director, Lazard. "2006 is looking like another exceptional year for the industry with a flood of new products entering late-stage development, supported by over $300 billion of investment capital."
Topics that will be highlighted in over 24 Investor Focus Session Panels include:
-- Five Cancer panels focusing on new breakthrough drugs and targets, emerging synergistic compounds, advances in pancreatic cancer, and cancer vaccine therapies. -- Panels to educate investors on new cholesterol drugs on the horizon, new hope for diabetes patients, pain management, obesity and Alzheimer's -- Two infectious disease panels highlighting the next wave of HIV drugs and breakthroughs in hepatitis B and C; and -- Several sessions on drug development that will discuss recent breakthroughs in hot areas such as Toll-like receptors, rapid genomic sequencing and personalized medicine.
* Average 2005 performance of the Nasdaq, AMEX and Dow Jones Biotechnology indices.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.Biotechnology Industry Organization
CONTACT: Erin Reese of the Biotechnology Industry Organization,+1-202-962-9200